Developed under the direction and sponsorship of Actelion Pharmaceuticals US, Inc. |
|
|
 |
|
 |
Dear [First_name_Last_name], |
Right heart catheterization is the gold standard test to diagnose pulmonary arterial hypertension (PAH),2,3 but it may not always be clear when to perform it. That is why we have developed the DETECT Screening Tool for PAH-SSc. Using a 2-step, noninvasive, and evidence-based algorithm, it can help you detect the need for confirmatory testing even in patients with mild disease.1 |
The DETECT study* included patients with systemic sclerosis (SSc) who1: |
 |
Were 18 years or older |
|
|
Were diagnosed more than 3 years ago |
|
|
Had a predicted DLCO <60% |
|
The DETECT Screening Tool for PAH-SSc is limited for use by healthcare specialists who treat SSc patients, and who are familiar with PAH as a complication of SSc. It is not intended to replace the medical or professional judgment of healthcare providers. It does not provide professional advice and should not be considered a diagnosis. Healthcare professionals using the tool should exercise clinical judgment as to the information they provide to the patient based upon the tool. |
You can download the free DETECT Screening Tool for PAH-SSc to your iPhone and Android devices. |
|
|
|
|
|
 |
 |
If you would like to learn more about PAH associated with connective tissue disease, please visit www.SuspectPAHCTD.com. |
|
* |
DETECT was an international cross-sectional study involving 62 experienced centers. DETECT was funded and supported by Actelion Pharmaceuticals Ltd. 488 patients with SSc enrolled between 2008 and 2011, and nearly 1 in 5 (18.7%, 87/466) were found to have PAH. Fifty-seven patients with PAH-SSc had follow-up data (median observation time, 12.6 months).1,4 |
|
References: 1. Coghlan JG, Denton CP, Grünig E, et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis. 2014;73(7):1340-1349. 2. Fischer A, Bull TM, Steen VD. Practical approach to screening for scleroderma-associated pulmonary arterial hypertension. Arthritis Care Res (Hoboken). 2012;64(3):303-310. 3. Galiè N, Humbert M, Vachiéry J-L, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2015;46(4):903-975. 4. Mihai C, Antic M, Dobrota R, et al. Factors associated with disease progression in early-diagnosed pulmonary arterial hypertension associated with systemic sclerosis: longitudinal data from the DETECT cohort. Ann Rheum Dis. 2018;77(1):128-132. |
App Store, the Apple logo, and iPhone are trademarks of Apple Inc. Google Play and the Google Play logo are trademarks of Google LLC. |
 |
©2020 Actelion Pharmaceuticals US Inc. All rights reserved. cp-171561v1 1120 |
|
Actelion Pharmaceuticals US, Inc.
5000 Shoreline Court, Suite 200
South San Francisco, CA 94080 |
|
e-M.D./alert was sent to you by /alert Marketing, Inc.
160 Chubb Avenue, Suite 304
Lyndhurst, NJ 07071 |
Be sure to add emdalert@emsg.alertmarketingmail.com
to your address book. |
Click here if you do not wish to receive further e-mails from e-M.D./alert. |
|
|
|
